免疫信息方法设计一种高效的针对黑色素瘤的多表位疫苗
Mahvash Dehghankhold1, Navid Nezafat2,3,4, Mitra Farahmandnejad2,3
1Department of Pharmaceutical Nanotechnology, Shiraz University of Medical Sciences, Shiraz, Iran.
Biotechnology and applied biochemistry
|September 9, 2024
概括
这项研究使用免疫信息学设计了一种新的多表位黑色素瘤疫苗. 计算分析表明,这种疫苗可以有效地刺激对黑色素瘤的免疫反应,提供一个有前途的治疗途径.
科学领域:
- 免疫学 免疫学 免疫学
- 计算生物学 计算生物学
- 在瘤学瘤学.
背景情况:
- 黑色素瘤是一种危险的皮肤癌,治疗选择有限.
- 目前的治疗方法可能会导致严重的副作用,并且可能无法治愈.
- 免疫疗法,特别是以表皮质为基础的疫苗,对黑色素瘤治疗有希望.
研究的目的:
- 使用免疫信息学设计一种多表位黑色素瘤疫苗.
- 为了提高疗效,将免疫原抗原 (NYESO-1,MAGE-C2) 和辅助剂 (BCSP31,RpfB,PADRE) 纳入.
- 通过计算来评估疫苗的物理化学,结构和免疫特性.
主要方法:
- 选择了NYESO-1和MAGE-C2抗原,因为它们在黑色素瘤中的高表达和免疫性.
- 整合了BCSP31,RpfB和PADRE以提高疫苗免疫性.
- 运用计算工具进行物理化学,结构和免疫特性评估.
- 进行了分子动力学和in silico免疫模拟.
主要成果:
- 设计的疫苗表现出有利的物理化学特性,过敏性和抗原性.
- 通过建模和验证,实现了高质量的三级结构.
- 证实了与TLR2和TLR4受体的稳定相互作用.
- 在模拟预测增加了辅助和细胞毒性T细胞,以及关键细胞因子 (IFN-γ,IL-2).
结论:
- 在 silico 设计的多表位黑色素瘤疫苗显示出作为有效的治疗策略的潜力.
- 该疫苗有效地刺激免疫反应,包括T细胞激活和细胞因子生产.
- 进一步的体外和体内研究对于验证疗效和安全至关重要.
更多相关视频
08:09Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
Published on: March 24, 2017
9.4K
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
1.2K
相关概念视频
Hybridoma Technology
14.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.1K
Antigens Involved in Adaptive Immunity
474
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
474
Cross-reactivity
31.0K
Overview
31.0K
